Cobra is currently expanding capacity in both Keele, UK and Matfors, Sweden.
Phil Ridley-Smith, Marketing Director
Cobra has seen a rapid increase in demand for its development and manufacturing services for ATMPs and moving forward will now focus its efforts on growing this area of the business. Cobra is currently expanding capacity in both Keele, UK and Matfors, Sweden to support demands for plasmid DNA, viral vectors and microbiota development and manufacturing services for our global customer base, with the aim of becoming a global leader in this exciting and growing market.
As a consequence, Cobra initiated a strategic review of its site located in Södertälje, Sweden, which is focussed on monoclonal antibody and mammalian protein development and manufacturing services. The outcome of this process cannot at this point be determined, but we are actively engaged in a process with our customers, employees at the site and interested parties to explore all potential options.